News - News - MicroPort® CardioFlow

News

Always Share with You
Every Bit of Our Progress

News

2022.01.06

MicroPort^® CardioFlow Receives Approval for VitaFlow Liberty^® in Argentina，Marking the Next Step in Its International Expansion

Read More
2021.12.28

MicroPort^® CardioFlow Has Completed the Submission of Application Materials of VitaFlow Liberty^TM for the EU CE Certification

Read More
2021.11.05

MicroPort^® CardioFlow Participates in the 32ND GW-ICC, Drawing Expert Attention on Clinical Application of Motorized Retrievable Valve System

Shanghai, China, 5 November 2021 — MicroPort® CardioFlow Medtech Corporation (CardioFlow Medtech) hosted a symposium for its next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™), during the 32nd Great Wall International Congress of Cardiology (GW-ICC) and Asia Heart Society Congress. The event brought together experts in the field of structural heart disease to share their experience on the clinical application of VitaFlow Liberty™.

Read More
2021.11.05

MicroPort^® CardioFlow Increases Investment in US Structural Heart Disease Innovator 4C Medical

Shanghai, China, 5 November 2021 — MicroPort® CardioFlow Medtech Corporation (02160.HK, MicroPort® CardioFlow) is set to become the largest shareholder of 4C Medical Technologies, Inc. (4C Medical) following the recent completion of a series C preferred shares subscription agreement. As the lead investor of the round, MicroPort® CardioFlow will make a strategic investment up to USD 25 million in 4C Medical, and will be granted the exclusive commercial rights to the investigational tricuspid products in China.

Read More
2021.10.30

MicroPort^® CardioFlow Launches VitaFlow Liberty™ at China Structural Week

Shanghai, China, 30 October 2021 — MicroPort® CardioFlow Medtech Corporation (MicroPort® CardioFlow) recently hosted a launch event for the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™), a next-generation product for transcatheter aortic valve implantation (“TAVI”). The product, presented at China Structural Week 2021 and the 5th China International Structural Heart Disease Conference held in Beijing, Shanghai, Guangzhou, and Xi'an, drew the attention of experts in the field of structural heart disease and triggered discussions on the development of the TAVI procedure.

Read More

<8 9 10 11 12 13 14 15 16 >

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

TOP

互联网药品信息服务资格证书编号：（沪）-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.